3D 生物学：下一代药物发现的范式转变 [交互式信息图表]
The drug discovery landscape is changing.
Bringing a drug to market has historically been time-consuming and costly, with many candidates failing in the first phase of clinical trials. Growing evidence suggests that screening compounds early in the process using traditional models – like animals, and cell cultures propagated in 2D – may be a contributing factor. Researchers are now navigating toward complex, human-relevant 3D systems like organoids, as they are believed to better represent how the body might respond to treatment.
在这里，我们更深入地探讨了为什么该行业将类器官用于下一代药物发现，并展示了在 3D 生物学领域为科学家提供支持的创新。
Has this inspired you to explore a transition from 2D to 3D biology? To find solutions for your organoid challenges? Or to scale the work you’re already doing?
Our experts can help. Reach out to us today to get started.